ATE337406T1 - Replikationsunfähige herpesviren zur verwendung in gentherapie - Google Patents

Replikationsunfähige herpesviren zur verwendung in gentherapie

Info

Publication number
ATE337406T1
ATE337406T1 AT00983421T AT00983421T ATE337406T1 AT E337406 T1 ATE337406 T1 AT E337406T1 AT 00983421 T AT00983421 T AT 00983421T AT 00983421 T AT00983421 T AT 00983421T AT E337406 T1 ATE337406 T1 AT E337406T1
Authority
AT
Austria
Prior art keywords
nervous system
central nervous
replicate
gene therapy
gene
Prior art date
Application number
AT00983421T
Other languages
English (en)
Inventor
Robert Stuart Coffin
Original Assignee
Biovex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovex Ltd filed Critical Biovex Ltd
Application granted granted Critical
Publication of ATE337406T1 publication Critical patent/ATE337406T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00983421T 1999-12-22 2000-12-22 Replikationsunfähige herpesviren zur verwendung in gentherapie ATE337406T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930418.0A GB9930418D0 (en) 1999-12-22 1999-12-22 Replication incompetent herpes virus vectors

Publications (1)

Publication Number Publication Date
ATE337406T1 true ATE337406T1 (de) 2006-09-15

Family

ID=10866883

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00983421T ATE337406T1 (de) 1999-12-22 2000-12-22 Replikationsunfähige herpesviren zur verwendung in gentherapie

Country Status (9)

Country Link
US (1) US6821753B2 (de)
EP (1) EP1240344B1 (de)
JP (1) JP2003518080A (de)
AT (1) ATE337406T1 (de)
AU (1) AU782932B2 (de)
CA (1) CA2395576A1 (de)
DE (1) DE60030324D1 (de)
GB (1) GB9930418D0 (de)
WO (1) WO2001046449A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930419D0 (en) * 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
ES2254359T3 (es) 2000-01-21 2006-06-16 Biovex Limited Cepa viral para el tratamiento oncolitico de canceres.
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
EP1694852B1 (de) 2003-11-17 2010-10-13 Crusade Laboratories Limited Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom
US9023617B2 (en) * 2004-02-17 2015-05-05 University Of Florida Research Foundation, Inc. Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression
CA2561714A1 (en) * 2004-04-08 2005-10-27 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
CN101203530A (zh) * 2004-10-28 2008-06-18 匹兹堡大学高等教育联邦体系 关于脊髓损伤疼痛的外周递送的谷氨酸脱羧酶基因治疗
US20100192236A1 (en) * 2009-01-28 2010-07-29 University Of South Carolina Modulation of Delta Opioid Receptor Expression
US20100284977A1 (en) * 2009-04-28 2010-11-11 University Of South Carolina Expression of Anti-Nociceptive Compounds from Endogenously Regulated Promoters
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
WO2015009952A1 (en) * 2013-07-17 2015-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production
ES2810800T3 (es) 2013-10-28 2021-03-09 Univ Pittsburgh Commonwealth Sys Higher Education Vector de HSV oncolítico
US10011199B2 (en) 2014-10-30 2018-07-03 Diono, Llc Rear facing ride down safety seat
RU2749050C2 (ru) 2016-01-27 2021-06-03 Онкорус, Инк. Онколитические вирусные векторы и их применение
JP6970086B2 (ja) 2016-04-08 2021-11-24 クリスタル バイオテック，インコーポレイティド 皮膚の創傷、障害、及び疾患を処置するための組成物及び方法
EP3658165A4 (de) 2017-07-26 2021-09-01 Oncorus, Inc. Onkolytische virusvektoren und verwendungen davon
CA3094345A1 (en) 2018-04-12 2019-10-17 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
WO2019210219A1 (en) 2018-04-27 2019-10-31 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
CA3112627A1 (en) 2018-09-24 2020-04-02 Krystal Biotech, Inc. Compositions and methods for the treatment of netherton syndrome
US10829529B2 (en) 2019-02-08 2020-11-10 Krystal Biotech, Inc. Compositions and methods for delivering CFTR polypeptides
CN114072517A (zh) * 2019-03-14 2022-02-18 麻省理工学院 工程化的单纯疱疹病毒-1(hsv-1)载体及其用途
WO2022170219A1 (en) 2021-02-05 2022-08-11 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
CN117412986A (zh) 2021-04-02 2024-01-16 克里斯托生物技术股份有限公司 用于癌症疗法的病毒载体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
GB9700411D0 (en) * 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
GB9810904D0 (en) * 1998-05-20 1998-07-22 Univ London Mutant herpes simplex viruses and uses thereof

Also Published As

Publication number Publication date
WO2001046449A1 (en) 2001-06-28
DE60030324D1 (de) 2006-10-05
EP1240344B1 (de) 2006-08-23
AU2017501A (en) 2001-07-03
GB9930418D0 (en) 2000-02-16
EP1240344A1 (de) 2002-09-18
AU782932B2 (en) 2005-09-08
US6821753B2 (en) 2004-11-23
JP2003518080A (ja) 2003-06-03
CA2395576A1 (en) 2001-06-28
US20030082142A1 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
ATE337406T1 (de) Replikationsunfähige herpesviren zur verwendung in gentherapie
Palmer et al. Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system
Liu et al. Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons
DE69636032D1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
Carlezon Jr et al. Herpes simplex virus-mediated gene transfer as a tool for neuropsychiatric research
Folini et al. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells
ATE331800T1 (de) Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor
Perng et al. A herpes simplex virus type 1 latency-associated transcript mutant with increased virulence and reduced spontaneous reactivation
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
DE69024809T2 (de) Herpes simplex virus typ 1 mutante
DK1252322T3 (da) Herpesvirusstamme til genterapi
GR3020557T3 (en) Oligonucleotide alkylphosphonates and alkylphosphonothioates.
Bennett et al. Improvement in erectile dysfunction after neurotrophic factor gene therapy in diabetic rats
IL181695A0 (en) Methods for cultivating cells and propagating viruses
CA2361892A1 (en) Treatment of tumors with genetically engineered herpes virus
WO2003016499A3 (en) Combinatorial methods for inducing cancer cell death
Wong et al. Systemic gene transfer of polyethylenimine (PEI)–plasmid DNA complexes to neonatal mice
JP7184337B2 (ja) 細胞傷害性免疫細胞による攻撃に対してがん細胞を増感させるためのｎｋｇ２ｄ活性化リガンドタンパク質の発現
FR2717824B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
Moore et al. Control of early Theiler's murine encephalomyelitis virus replication in macrophages by interleukin-6 occurs in conjunction with STAT1 activation and nitric oxide production
Cuchet et al. HSV-1 amplicon vectors: a promising and versatile tool for gene delivery
Keller et al. Role of the human cytomegalovirus major immediate-early promoter's 19-base-pair-repeat cyclic AMP-response element in acutely infected cells
Fukuhara et al. Triple‐mutated oncolytic herpes virus for treating both fast‐and slow‐growing tumors
MX2022001080A (es) Metodos y composiciones para reducir la inmunogenicidad mediante inhibidores de celulas b no agotadores.
WO1999047678A3 (en) Interferon alpha plasmids and delivery systems, and methods of making and using the same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties